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Edited by Laszlo NagyAbstract Multinuclear osteoclasts are derived from CD11b-po-
sitive mononuclear cells in bone marrow and in circulation.
FACS sorting experiments showed impaired osteoclastogenesis
in RAW264.7 cells with low CD11b expression. Neutralizing
antibodies and siRNA against CD11b inhibited osteoclastogene-
sis induced by RANKL. Although primary cultured mouse bone
marrow macrophages expressed CD11a and CD11b, osteo-
clastogenesis induced by M-CSF and RANKL was inhibited in
the presence of anti-CD11b or anti-CD18 but not anti-CD11a
antibodies. Furthermore, anti-CD11b antibodies inhibited
NFATc1 expression induced by M-CSF and RANKL in BMMs.
These ﬁndings suggest, at least partly, an important role of
CD11b in osteoclastogenesis.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Osteoclasts are multinucleated bone-resorbing cells formed
by the fusion of mononuclear cells derived from the mono-
cyte/macrophage lineage (osteoclast precursors (pre-OCs)).
Pre-OCs in the peripheral circulation or within the bone mar-
row are separated from the bone surface by endothelial cells
lining the blood vessels [1]. Therefore, the extravasation and
the migration under osteoblasts are necessary for pre-OCs to
reach the surface of the bone matrix [2]. After pre-OCs diﬀer-
entiate into tartrate-resistant acid phosphatase (TRAP)-posi-
tive mononuclear cells, these cells diﬀerentiate into
multinucleated osteoclasts by cell fusion [3].
Adhesion molecules are necessary for leukocyte traﬃcking
and diﬀerentiation. Integrins are one of the most important
adhesion molecule family involved in traﬃcking of mono-
cyte/macrophage. Integrins are non-covalentry linked ab het-
erodimers. Four a subunits and b2 subunit were expressed
on macrophages (aLb2, CD11a/CD18; aMb2, CD11b/CD18;*Corresponding author. Fax: +81 5803 0212.
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Among them, CD11a/CD18 integrin pair (leukocyte func-
tion-associated antigen-1, LFA-1) and CD11b/CD18 integrin
pair (macrophage antigen 1, Mac-1) were expressed on pre-
OCs and play important roles during osteoclastogenesis. Inter-
cellular adhesion molecule-1 (ICAM-1, CD54) on endothelial
cells is reported to play an important role in the extravasation
of pre-OCs [1], and the candidates of counter receptors against
ICAM-1 are LFA-1 and Mac-1, which are expressed on
pre-OCs. As for the interaction between osteoblasts and pre-
OCs, the involvement of ICAM-1 and LFA-1 in osteoclasto-
genesis has been reported [5–8]. In addition to the interactions
between heterologous cells via integrin, it was also reported
that direct interactions mediated by ICAM-1/LFA-1 among
pre-OCs contribute to osteoclastogenesis [5,8,9]. Although
one of the best markers of osteoclast precursors is Mac-1
[10,11], to our knowledge there have been no studies to exam-
ine the role of Mac-1 in osteoclastogenesis.
This study examined the possible role of Mac-1 in osteo-
clastogenesis using RAW264.7 cells and primary cultured bone
marrow macrophages (BMMs). It is reported here that Mac-1
may play an important role in the early stage of osteoclasto-
genesis via the communication between pre-OCs.2. Materials and methods
2.1. RAW264.7 cell culture and induction of osteoclast formation
The RAW 264.7 cell line used in this study was kindly provided by
Dr. T. Suda (Showa University) and grown in a-MEM supplemented
with 10% fetal calf serum (FCS) (growth medium) in a CO2 incubator.
RAW264.7cells were seeded in the center of the wells of a 48-well plate
for spot culture (3–100 ll of 105 cells/ml) and incubated for 30 min.
Then the medium was replaced with 0.5 ml of growth medium contain-
ing 10% FCS and 50 ng/ml of soluble RANKL (sRANKL, Oriental
Yeast Co. Ltd.) and the cultures were incubated for 5 days. For uni-
form cell cultures, cells with diﬀerent densities (6–200 · 102 cells/ ml)
were prepared, and 0.5 ml of cell suspension was seeded into the wells
of a 48-well plate and incubated for 30 min. Osteoclast formation was
induced by medium replacement with growth medium containing
50 ng/ml of sRANKL. Functional blocking experiments were carried
out in spot culture conditions (1000 cells/ 10 ll) with 10 lg/ml of rat
IgG2b, IgG2a (Functional Grade, eBioscience) or antibodies (anti-
CD11a, M17/4; anti-CD11b, M1/70; or anti-CD18, M18/2, Functional
Grade, eBioscience). Tartrate-resistant acid phosphatase positive
(TRAP+) multinuclear cells were detected using TRAP staining at 5
days after sRANKL treatment.blished by Elsevier B.V. All rights reserved.
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CD11bLow, CD11bMed, and CD11bHigh RAW264.7 cell populations
were individually isolated by FACS (FACS Aria, BD Bioscience).
Brieﬂy, RAW264.7 cells were stained with PE-labeled anti-CD11b
and FITC-labeled anti-CD54 antibodies (clone M1/70, clone YN/
1.7.4, eBioscience). After washing the cells three times with phosphate
buﬀered saline (PBS) containing 2 mM EDTA, the cells were separated
by the degree of CD11b expression using FACS.
2.3. Knockdown of CD11b in RAW264.7 cells
RAW264.7 cells (1.5 · 106) were cultured in a 6 cm dish (Falcon)
with growth medium for 24 h. An expression plasmid encoding a short
hairpin RNA against CD11b and green ﬂuorescent protein
(GFP)(SureSilencing shRNA plasmid for Mouse Itgam, clone 2, for
control clone NC, SuperArray) was transiently transfected into the
cells using Lipofectamine 2000 Reagent (Invitrogen). Two days after
transfection, the cells were stained with PE-labeled anti-CD11b (clone
M1/70, eBioscience) to conﬁrm CD11b knockdown. CD11b expression
of cells was analyzed and GFP positive cells were isolated using FACS.
2.4. Mouse bone marrow macrophage culture and induction of osteoclast
formation
Male mice were euthanized, and femurs and tibias were obtained.
Sterile bone marrow preparations were obtained by ﬂushing the femurs
and tibias with PBS using a 27-gauge needle. After washing, red blood
cells were lysed using 0.83% ammonium chloride solution. The sus-
pended cell solution was passed through a 70 lm cell strainer (BD Fal-
con) to remove large cell debris. The mononuclear cells obtained were
seeded in a 48-well plate at a density of 106 cells/well and cultured with
macrophage colony-stimulating factor-containing (M-CSF, 10 ng/ml,
Peprotech) growth medium. Osteoclast formation was induced by
medium replacement with growth medium containing M-CSF (10 ng/
ml) and sRANKL (100 ng/ml) at 24 h after the start of bone marrow
macrophage (BMM) culture. TRAP+ multinuclear cells were detected
using TRAP staining at 3 days after M-CSF and sRANKL treatment.
2.5. Quantiﬁcation of NFATc1 mRNA by real-time RT-PCR
Total RNA was extracted from the BMMs at 24 h after the start of
treatment of the cells with M-CSF and sRANKL in the presence of rat
IgG or anti-CD11b antibody using TRIZOL Reagent according to the
manufacturers protocol (Invitrogen). Two micrograms of total RNA
was subjected to reverse-transcription (ReveTra Ace, TOYOBO).
The cDNA samples were ampliﬁed with Platinum SYBR Green qPCR
SuperMix-UDG with ROX (Invitrogen). All the data were analyzed by
the comparative Ct Method (7500 Fast Real-Time PCR System, Ap-
plied Biosystems, Foster City, CA, USA). NFATc1-speciﬁc primers
were 5 0- CAACGCCCTGACCACCGATAG-3 0 (forward) and 5 0-
GGCTGCCTTCCGTCTCATAGT-3 0 (reverse); GAPDH-speciﬁc
primers were 5 0- TACAGCAACAGGGTGGTGGAC-3 0 (forward)
and 5 0- GTGGGTGCAGCGAACTTTATT-3 0 (reverse).Fig. 1. Cell density dependent diﬀerentiation of RAW264.7 cells. (A) RAW
wells (0.785 cm2). (B) RAW264.7 cells were seeded with four diﬀerent numbe
TRAP+ multinuclear cells at 5 days after sRANKL (50 ng/ml) treatment. B2.6. Tartrate-resistant acid phosphatase (TRAP) staining
Osteoclast formation was evaluated using TRAP staining because it
is well known that TRAP expression gradually increases during osteo-
clast diﬀerentiation. After the cells were washed with phosphate buf-
fered saline (PBS), they were ﬁxed with ethanol/acetone (4:1) for
1 min. The cultures were then dried and stained for TRAP by incubat-
ing them in 0.05 M sodium acetate buﬀer (pH 5.0) containing naphthol
AS-BI phosphoric acid sodium salt (Sigma) and fast red ITR salt (Sig-
ma) in the presence of 10 mM sodium tartrate (Sigma). TRAP-positive
cells with three or more nuclei formed in the culture system were con-
sidered to be osteoclast-like multinuclear cells. The area occupied by
osteoclast-like cells in low-power ﬁeld (2.18 mm · 1.8 mm) was ana-
lyzed and represented by OC area.3. Results
3.1. Diﬀerentiation of RAW264.7 cells into multinuclear
osteoclasts is cell density dependent
According to a previous report, osteoclastogenesis induced
by sRANKL is dependent on the cell density of the precursor
cells [12]. Firstly, it was examined whether the sRANKL in-
duced osteoclastogenesis was dependent on the cell density of
RAW264.7 cells. When RAW264.7 cells were seeded in the
wells of a 48-well plate at diﬀerent densities, osteoclastogenesis
was found to be dependent on cell-density (Fig. 1A). On the
other hand, when the RAW264.7 cells were seeded in the wells
at the same density but with diﬀerent cell numbers, osteoclasto-
genesis was induced independently the number of RAW264.7
cells (Fig. 1B). These results suggest that the osteoclastogenesis
induced by sRANKL is dependent on the initial cell density.
3.2. Impaired osteoclastogenesis in CD11bLow RAW 264.7 cells
It was hypothesized that the cell density-dependent osteo-
clastogenesis may be the result of impairment of cell–cell con-
tact at low cell density at the early stage of osteoclastogenesis.
Usually, cell communication is achieved by intercellular adhe-
sion. It was reported that RAW264.7 cells and macrophages
express the cell adhesion molecules ICAM-1 and Mac-1 [5,8–
10,13]. Therefore, the expression of ICAM-1 and Mac-1 in
RAW264.7 cells was analyzed using FACS. Although the
ICAM-1 expression level was not diﬀerent among
RAW264.7 cells, there were heterogeneous populations with
varying expression levels of CD11b (Fig. 2A). After these pop-264.7 cells were seeded at four diﬀerent densities in equal sized culture
rs of cells but the same density (100 cells/ll). Representative images of
ar = 300 lm.
Fig. 2. The relationship Mac-1 expression and osteoclast diﬀerentiation in RANKL-stimulated RAW264.7 cells. (A) FACS analysis of RAW264.7
cells. Heterogeneity of CD11b expression was noted. Three populations (CD11bLow, CD11bMed, and CD11bHigh) were isolated. (B) Osteoclast
diﬀerentiation was induced with sRANKL (50 ng/ml) in each population. Values are presented as means ± S.E., n = 4, *P < 0.05 vs parent group.
Analysis of variance followed by Dunnett 0s test. (C) Representative images of TRAP+ multinuclear cells at 5 days after sRANKL treatment.
Bar = 300 lm.
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Fig. 2A), osteoclastogenesis was induced by sRANKL. As
shown in Fig. 2B, osteoclastogenesis was severely impaired
in the population with low CD11b expression. This result
may indicate an important role of CD11b on osteoclastogene-
sis in RAW264.7 cells.
3.3. Osteoclastogenesis was attenuated by Mac-1 blockage in
RAW264.7 cells
A previous study demonstrated that the expression level of
Mac-1 was dependent on the stage of osteoclast diﬀerentiation
[3]. Therefore, the diﬀerentiation stages of osteoclastogenesis
among the FACS sorted populations may reﬂect their ability
for osteoclastogenesis. To exclude this possibility, the eﬀect
of neutralizing antibodies on osteoclastogenesis was examined
in RAW264.7 cells. Osteoclastogenesis was not aﬀected by the
treatment of the cells with rat IgG2b or IgG2a (IgG2a, data
not shown). Not only an anti-CD11b antibody but also an
anti-CD18 antibody signiﬁcantly inhibited the osteoclasto-
genesis induced by sRANKL. On the other hand, an anti-
CD11a antibody did not aﬀect the osteoclastogenesis
(Fig. 3A and B). This result strongly suggests an important
role of Mac-1 on osteoclastogenesis in RAW264.7 cells.
3.4. CD11b knockdown and osteoclastogenesis
To conﬁrm the important role of Mac-1 in osteoclastogene-
sis, speciﬁc knockdown of CD11b by RNA interference was
performed. FACS analysis showed an approximately 50% de-
crease in CD11b expression was achieved in GFP positive
RAW264.7 cells (data not shown). Osteoclastogenesis tended
to decrease in CD11b knockdown cells in comparison to con-
trol RAW264.7 cells (Fig. 4).
3.5. Role of Mac-1 in osteoclastogenesis in bone marrow
macrophages
The role of Mac-1 in osteoclastogenesis in primary cultured
BMMs was examined. Osteoclastogenesis was not aﬀected bythe treatment of the cells with rat IgG2b or IgG2a (IgG2a,
data not shown). As shown in Fig. 5, osteoclastogenesis of
BMMs induced by M-CSF and sRANKL was inhibited by
treatment of the cells with antibodies against CD11b and
CD18. Anti-CD11a antibody did not aﬀect osteoclastogenesis
in BMMs.
3.6. Blockage of CD11b by a neutralizing antibody inhibited
mRNA expression of nuclear factor of activated T cells c1
To clarify the involvement of the inhibitory eﬀect of the anti-
CD11b antibody on osteoclastogenesis in the early stage of dif-
ferentiation, the mRNA expression level of nuclear factor of
activated T cells c1 (NFATc1) in BMMs was examined at
24 h after M-CSF and sRANKL treatment. More than a 3-
fold increase in NFATc1 mRNA levels was detected in the
cells treated with M-CSF and sRANKL. This NFATc1 up-
regulation was signiﬁcantly inhibited by treatment of the cells
with the anti-CD11b antibody (Fig. 6). This result suggests, at
least in part, an important role of Mac-1 in osteoclastogenesis
in the early diﬀerentiation stage.4. Discussion
A decade ago, the ﬁrst step in the molecular elucidation of
osteoclast diﬀerentiation was achieved with the discovery of
RANKL (also known as OPGL, ODF, or TRANCE)
[14,15]. RANKL binds to its receptor, RANK, which is ex-
pressed in pre-OCs and induces the osteoclast diﬀerentiation
of pre-OCs via TNF receptor-associated factor 6 (TRAF6)
activation. Genome-wide screening and gain/loss of function
experiments revealed the important role of NFATc1, a master
regulator of osteoclastogenesis, following induction by
RANKL [16,17]. In addition to RANK/RANKL signaling,
it has been revealed that immunoreceptor tyrosine-based acti-
vation motif (ITAM)-dependent co-stimulatory signals are in-
volved in osteoclastogenesis by the elevation of cytosolic Ca2+
Fig. 3. Eﬀect of antibodies on osteoclast diﬀerentiation in RAW264.7 cells. (A) Representative images of TRAP+ multinuclear cells at 5 days after
sRANKL treatment. (a) sRANKL (); (b) sRANKL+ (control); (c) sRANKL+IgG (IgG2b); (d) sRANKL+anti-CD18 Ab (anti-CD18); (e)
sRANKL+ anti-CD11a Ab (anti-CD11a); and (f) sRANKL+ anti-CD11b Ab (anti-CD11b). Bar = 300 lm. (B) Quantiﬁcation of TRAP+ osteoclast
diﬀerentiation at 5 days after treatment with sRANKL (50 ng/ml) and antibodies (10 lg/ml). Values are presented as means ± S.E., n = 4, *P < 0.05
vs IgG group. Analysis of variance followed by Dunnett 0s test.
Fig. 4. Eﬀect of CD11b knockdown by shRNA on RAW264.7 cell
diﬀerentiation. (A) Representative images of TRAP+ multinuclear cells
at 5 days after sRANKL treatment. (a) negative-shRNA (GFP+) and
(b) CD11b-shRNA (GFP+). Bar = 300 lm. (B) Quantiﬁcation of
TRAP+ osteoclast diﬀerentiation at 5 days after treatment with
sRANKL (50 ng/ml). Values are presented as means ± S.E., n = 4.
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shown that mice lacking ITAM-harboring adaptors, Fc recep-
tor c subunit (FcRc) and DNAX-activating protein (DAP) 12,
exhibit severe osteopetrosis owing to impaired osteoclast dif-ferentiation. It was supposed that the phosphorylation of
ITAM results in the recruitment of spleen tyrosine kinase
(Syk), and subsequently Syk activates calcium signaling via
phospholipase C (PLC).
In this study, it was found that functional impairment of
Mac-1 resulted in inhibition of osteoclast diﬀerentiation in
both RAW264.7 cells and BMMs using neutralizing antibodies
and a gene silencing technique. The essential role of Syk in
integrin-mediated leukocyte activation and Syk co-localization
with CD18 have been reported [20–25]; therefore, the inhibi-
tion of osteoclastogenesis might be the result of the attenua-
tion of Syk signaling by the functional blockage of Mac-1.
Interestingly, Mo´csai et al. reported that the activation of
Syk by integrins required DAP12 and FccR [26]. Conversely,
the osteopetrotic phenotype of double knockout mice
(DAP12/ and FccR/) may be partly due to a lack of inte-
grin signaling in these mice. In this study, RANKL-induced in-
creases in NFATc1 mRNA levels were inhibited by the
treatment of BMMs with a neutralizing antibody against
CD11b. This result suggests that integrin signaling plays an
important role as a co-stimulatory molecule in the early osteo-
clast diﬀerentiation of BMMs induced by M-CSF and
sRANKL.
The counter receptors for Mac-1 were thought to be ICAM-
1 and -2, which are expressed in pre-OCs and macrophages
[5,8,9,27]. BMMs expressed both ICAM-1 and -2, and
Fig. 5. Eﬀect of antibodies on osteoclast diﬀerentiation in BMMs. (A) Representative images of TRAP+ multinuclear cells at 3 days after M-CSF
(10 ng/ml) and sRANKL (100 ng/ml) treatment. (a) M-CSF; (b) M-CSF + sRANKL (control); (c) M-CSF+ sRANKL+IgG (IgG2b); (d) M-
CSF + sRANKL + anti-CD18 Ab (anti-CD18); (e) M-CSF + sRANKL + anti-CD11a Ab (anti-CD11a); (f) M-CSF + sRANKL + anti-CD11b Ab
(anti-CD11b). Bar = 300 lm. (B) Quantiﬁcation of TRAP+ osteoclast diﬀerentiation at 3 days after treatment with sRANKL (100 ng/ml), M-CSF
(10 ng/ml), and antibodies (10 lg/ml). Values are presented as means ± S.E., n = 6, *P < 0.05 vs IgG group. Analysis of variance followed by
Dunnetts test.
Fig. 6. Eﬀect of anti-CD11b antibody on NFATc1 expression in
BMMs. Quantiﬁcation of NFATc1 mRNA expression at 24 h after
treatment of sRANKL (100 ng/ml), M-CSF (10 ng/ml), and antibody
(10 lg/ml). Control, M-CSF; IgG, M-CSF + sRANKL + IgG2b, anti-
CD11b, M-CSF + sRANKL + anti-CD11b Ab. Values are presented
as means ± S.E., n = 7, *P < 0.05 vs control group. #P < 0.05 vs IgG
group. Analysis of variance followed by Tukey–Kramer multiple
comparison test.
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current experiment, RANKL-induced osteoclastogenesis was
dependent on the cell density of pre-OCs but not on the num-ber of pre-OCs. In addition to RANKL signaling, Mac-1 occu-
pancy with ICAMs may trigger the diﬀerentiation of pre-OCs
via ITAM-harboring adaptors as mentioned above. This
hypothesis may explain the advantage of cell–cell communica-
tion in the diﬀerentiation of pre-OCs, because pre-OCs must
recognize the existence of other pre-OCs to fuse with each
other before the beginning of osteoclast diﬀerentiation. A re-
cent report showed that the phosphorylation of CD11b was re-
quired for integrin activation to bind to ICAMs [28], but the
molecule that triggers the phosphorylation of CD11b remains
to be determined.
In conclusion, this study showed the importance of the den-
sity of pre-OCs in osteoclast diﬀerentiation induced by
sRANKL. This observation led to the hypothesis that commu-
nication among pre-OCs plays an important role in the begin-
ning of osteoclast diﬀerentiation. Integrin blockage
experiments revealed the involvement of Mac-1 in osteoclast
diﬀerentiation induced by sRANKL. Moreover, the expression
of NFATc1 mRNA induced by RANKL was, at least in part,
dependent on integrin occupancy. Collectively, the current
ﬁndings demonstrate the possible role of integrin in early
osteoclast diﬀerentiation. These results will contribute to the
molecular understanding of osteoclastogenesis.
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